Back to Search
Start Over
Metyrosine Treatment in a Woman with Chromosome 22q11.2 Deletion Syndrome and Psychosis: A Case Study
- Source :
-
International Journal of Developmental Disabilities . 2019 65(2):116-121. - Publication Year :
- 2019
-
Abstract
- Background: People with 22q11.2 deletion syndrome (DS) are assumed to be especially vulnerable to developing mental illness such as psychosis. Aim: The study was established to contribute to knowledge about metyrosine medication in patients with 22q11.2 DS and psychosis. Methods: A case study was established including a woman with intellectual disability, 22q11.2 DS, and psychosis. Metyrosine medication was implemented, as conventional anti-psychotic medication was unsuccessful. Results: Effect of metyrosine medication included both psychotic symptom relief with decreased aggressive behaviour. Adjunctive milieu therapy contributed to compliance. Conclusion: For patients with 22q11.2 DS and psychosis, metyrosine medication may prove effective. However, there are significant ethical dilemmas related to metyrosine medication for psychotic symptoms.
Details
- Language :
- English
- ISSN :
- 2047-3869
- Volume :
- 65
- Issue :
- 2
- Database :
- ERIC
- Journal :
- International Journal of Developmental Disabilities
- Publication Type :
- Academic Journal
- Accession number :
- EJ1226497
- Document Type :
- Journal Articles<br />Reports - Research
- Full Text :
- https://doi.org/10.1080/20473869.2017.1401257